Hence, antibody-engineered marrow macrophages/monocytes in marrow with SIRPα-blockade and clinically relevant anti-Tyrp1 [23] can in principle out-compete and thereby repress human metastatic melanoma. Here, SIRPA is linked to metastatic melanoma.